Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains

Overview

Journal Vaccines (Basel)

Date 2021 Aug 28

PMID 34452044

Citations 16

Authors

Ki-Back Chu

Hae-Ji Kang

Keon-Woong Yoon

Hae-Ahm Lee

Eun-Kyung Moon

Beom-Ku Han

Fu-Shi Quan

Affiliations

Soon will be listed here.

Abstract

The ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic had brought disastrous consequences throughout the entire world. While several manufactured vaccines have been approved for emergency use, continuous efforts to generate novel vaccines are needed. In this study, we developed SARS-CoV-2 virus-like particles (VLPs) containing the full length of spike (S) glycoprotein (S full), S1, or S2 together with the influenza matrix protein 1 (M1) as a core protein. Successfully constructed VLPs expressing the S full, S1, and S2 via Sf9 cell transfections were confirmed and characterized by Western blot and transmission electron microscopy (TEM). VLP immunization in mice induced higher levels of spike protein-specific IgG and its subclasses compared to naïve control, with IgG2a being the most predominant subclass. S full and S1 immune sera elicited virus-neutralizing activities, but these were not strong enough to fully inhibit receptor-ligand binding of the SARS-CoV-2. Neutralizing activities were not observed from the S2 VLP immune sera. Overall, our findings revealed that S full or S1 containing VLPs can be developed into effective vaccines.

Citing Articles

Recent Advances in Antiviral Drug Delivery Strategies.

Rana D, Prajapati A, Karunakaran B, Vora L, Benival D, Jindal A AAPS PharmSciTech. 2025; 26(3):73.

PMID: 40038154 DOI: 10.1208/s12249-025-03053-3.

Development and Evaluation of a Newcastle Disease Virus-like Particle Vaccine Expressing SARS-CoV-2 Spike Protein with Protease-Resistant and Stability-Enhanced Modifications.

Chen Y, Tian F, Hu S, Liu X Viruses. 2025; 16(12.

PMID: 39772238 PMC: 11680274. DOI: 10.3390/v16121932.

Dimming the corona: studying SARS-coronavirus-2 at reduced biocontainment level using replicons and virus-like particles.

Neilsen G, Mathew A, Castro J, McFadden W, Wen X, Ong Y mBio. 2024; 15(12):e0336823.

PMID: 39530689 PMC: 11633226. DOI: 10.1128/mbio.03368-23.

Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.

Henriquez R, Munoz-Barroso I Heliyon. 2024; 10(15):e34927.

PMID: 39144987 PMC: 11320483. DOI: 10.1016/j.heliyon.2024.e34927.

Nanoparticles and Antiviral Vaccines.

Liu S, Hu M, Liu X, Liu X, Chen T, Zhu Y Vaccines (Basel). 2024; 12(1).

PMID: 38250843 PMC: 10819235. DOI: 10.3390/vaccines12010030.

References

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Martinez M, Capella Gonzalez C, Huey D, Peeples M, McCarty D, Niewiesk S . Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats. PLoS One. 2021; 16(2):e0246770. PMC: 7891763. DOI: 10.1371/journal.pone.0246770. View

Kirkpatrick Roubidoux E, Carreno J, McMahon M, Jiang K, van Bakel H, Wilson P . Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model. mBio. 2021; 12(1). PMC: 8545130. DOI: 10.1128/mBio.03617-20. View

Wang B, Quan F, Kang S, Bozja J, Skountzou I, Compans R . Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol. 2008; 82(23):11813-23. PMC: 2583664. DOI: 10.1128/JVI.01076-08. View

Chu K, Quan F . Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites. Curr Top Microbiol Immunol. 2021; 433:77-106. DOI: 10.1007/82_2021_232. View

Tan C, Chia W, Qin X, Liu P, Chen M, Tiu C . A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020; 38(9):1073-1078. DOI: 10.1038/s41587-020-0631-z. View

Steel J, Lowen A, Wang T, Yondola M, Gao Q, Haye K . Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio. 2010; 1(1). PMC: 2912658. DOI: 10.1128/mBio.00018-10. View

Mansour A, Banik S, Suresh R, Kaur H, Malik M, McCormick A . An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia. Front Microbiol. 2018; 9:1195. PMC: 5996085. DOI: 10.3389/fmicb.2018.01195. View

Karthik K, Senthilkumar T, Udhayavel S, Raj G . Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19. Hum Vaccin Immunother. 2020; 16(12):3055-3060. PMC: 7484565. DOI: 10.1080/21645515.2020.1796425. View

10.

Chan S, Du P, Ignacio C, Mehta S, Newton I, Steinmetz N . Biomimetic Virus-Like Particles as Severe Acute Respiratory Syndrome Coronavirus 2 Diagnostic Tools. ACS Nano. 2020; 15(1):1259-1272. DOI: 10.1021/acsnano.0c08430. View

11.

Tay M, Poh C, Renia L, Macary P, Ng L . The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20(6):363-374. PMC: 7187672. DOI: 10.1038/s41577-020-0311-8. View

12.

Berry J, Hay K, Rini J, Yu M, Wang L, Plummer F . Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs. 2010; 2(1):53-66. PMC: 2828578. DOI: 10.4161/mabs.2.1.10788. View

13.

Lee S, Kang H, Lee D, Kang S, Quan F . Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection. Vaccine. 2018; 36(38):5692-5700. DOI: 10.1016/j.vaccine.2018.08.016. View

14.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

15.

Xu R, Shi M, Li J, Song P, Li N . Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System. Front Bioeng Biotechnol. 2020; 8:862. PMC: 7409377. DOI: 10.3389/fbioe.2020.00862. View

16.

Zhong L, Haynes L, Struble E, Tamin A, Virata-Theimer M, Zhang P . Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein. Biochem Biophys Res Commun. 2009; 390(3):1056-60. PMC: 7092930. DOI: 10.1016/j.bbrc.2009.10.115. View

17.

Tang J, Tambyah P, Hui D . Emergence of a new SARS-CoV-2 variant in the UK. J Infect. 2020; 82(4):e27-e28. PMC: 7834693. DOI: 10.1016/j.jinf.2020.12.024. View

18.

Ding S, Laumaea A, Benlarbi M, Beaudoin-Bussieres G, Gasser R, Medjahed H . Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization. Viruses. 2020; 12(11). PMC: 7692607. DOI: 10.3390/v12111214. View

19.

Schoeman D, Fielding B . Coronavirus envelope protein: current knowledge. Virol J. 2019; 16(1):69. PMC: 6537279. DOI: 10.1186/s12985-019-1182-0. View

20.

Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C . Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020; 180(10):1356-1362. PMC: 9377417. DOI: 10.1001/jamainternmed.2020.4616. View